89.4%
advanced solid malignancyadvanced solid malignanciesBASECAMP-1logic-gated Tmod chimeric antigen receptor T-cell therapiesBASECAMP-1A2 BiotherapeuticsTempus AI
…pies. Eligible patients for these interventional trials have an advanced solid malignancy and are germline human leucocyte antigen (HLA)-A*02 heterozygou…